Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CD44 | P16070 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | NQO1 | P15559 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
| ▸ | PGK1 | P00558 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17299129 | 0.75 | NQO1 (0.33) | NQO1 | |
| SCHEMBL8479600 | 0.75 | GAA (0.48) | GAACD44TSHRCYP3A4TP53 | |
| SCHEMBL8478664 | 0.71 | CD44 (0.46) | GAACD44CYP3A4PGK1ALDH1A1 | |
| SCHEMBL15330049 | 0.71 | TDP1 (0.34) | GAANQO1TDP1 | |
| SCHEMBL15570972 | 0.70 | ALDH1A1 (0.46) | TSHRCYP3A4TP53ALDH1A1MAPK1 | |
| SCHEMBL12477761 | 0.70 | ALDH1A1 (0.43) | GAATSHRCYP3A4ALDH1A1MAPK1 | |
| SCHEMBL11358955 | 0.67 | TDP1 (0.35) | TSHRCYP3A4ALDH1A1MAPK1TDP1 | |
| SCHEMBL296626 | 0.67 | PTK2 (0.50) | GAANQO1ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL22686894 | 0.64 | PTK2 (0.47) | GAANQO1ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL5861979 | 0.64 | PTK2 (0.47) | GAANQO1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20240101558-A1 | AMPK ACTIVATORS | KALLYOPE, INC. | 2024-03-28 | — | — | US | disclosed |
| US-11851429-B2 | AMPK activators | KALLYOPE, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| CN-116390925-A | AMPK activator | 卡尔优普公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-116323608-A | AMPK activator | 卡尔优普公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023097190-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097190-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097189-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023097189-A1 | AMPK ACTIVATORS | KALLYOPE, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-4172162-A1 | AMPK ACTIVATORS | Kallyope, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-2888008-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2888006-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-07-01 | — | — | EP | disclosed |
| EP-2888005-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2015-07-01 | — | — | EP | disclosed |
| US-8796258-B2 | Cyclic azabenzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP. (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2014031515-A1 | NOVEL AZABENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014031465-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROPYRAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014031517-A1 | NOVEL AZABENZIMIDAZOLE TETRAHYDROFURAN DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | WO | disclosed |
| EP-2677869-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | Merck Sharp & Dohme Corp. (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20130123237-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2012116145-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2012-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | GAA 3152/4885CD44 4828/4885TSHR 919/4885 |
| US-20130123237-A1 | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAB2, PRKAG1 | GAA 1067/4885CD44 4819/4885TSHR 3406/4885 |
| US-11851429-B2 | AMPK activators | PRKAG1, PRKAG2, PRKAG3 | GAA 544/4885CD44 4536/4885TSHR 2028/4885 |
| US-20240101558-A1 | AMPK ACTIVATORS | PRKAG1, PRKAG2, PRKAG3 | GAA 544/4885CD44 4536/4885TSHR 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.